Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for metabolic and endocrine disorder. The Company�s clinical program is VK0612, an orally available drug candidate entering a Phase IIb clinical trial for type II diabetes. The Company�s clinical program is VK5211, an orally available drug candidate entering a Phase II clinical trial for the treatment of cancer cachexia, a complex disease characterized by an uncontrolled decline in muscle mass. VK5211 is designed to selectively produce the therapeutic benefits of testosterone in muscle tissue, with improved safety, tolerability and patient acceptance compared with administration of exogenous testosterone. VK0612 is a potent, selective inhibitor of fructose-1,6-bisphosphatase, (FBPase), an enzyme that plays a role in endogenous glucose production, or the synthesis of glucose by the body.